Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 144,911	$ 124,775
Short-term investments	17,427	42,086
Accounts receivable	36,415	33,729
Prepaid clinical development costs	6,916	1,026
Inventories, net	39,352	35,201
Other prepaid and current assets	5,584	9,866
Total current assets	250,605	246,683
Property and equipment, net	83	164
Right of use operating lease assets	1,075	1,036
Intangible assets	56	56
Total assets	251,819	247,939
Current liabilities:
Accounts payable	17,065	23,040
Accrued clinical development costs	4,617	5,426
Other accrued liabilities	34,421	35,191
Revenue interest liability	26,921	24,760
Deferred revenue from collaborations	12,157	3,507
Operating lease liabilities	305	384
Total current liabilities	95,486	92,308
Convertible notes, net of issuance costs	260,316	259,899
Revenue interest liability	224,898	218,845
Operating lease liabilities	782	665
Total liabilities	581,482	571,717
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 240,000,000 shares authorized as of March 31, 2023 and as of December 31, 2022; 89,237,167 shares issued at March 31, 2023 and 76,564,396 shares issued at December 31, 2022	87	75
Additional paid-in capital	1,127,004	1,071,183
Treasury stock, at cost; 1,994,198 shares at March 31, 2023 and December 31, 2022	(54,998)	(54,998)
Accumulated other comprehensive loss	(1)	(2)
Accumulated deficit	(1,401,755)	(1,340,036)
Total stockholders’ deficit	(329,663)	(323,778)
Total liabilities and stockholders’ deficit	$ 251,819	$ 247,939